Tapentadol

For the clinical treatment of moderate to severe chronic pain, opioids have long had clinical pain points of high addiction risk and frequent adverse reactions. The advent of tapentadol provides a safer option for such patients. As a centrally acting opioid analgesic, it has a dual mechanism of action: on the one hand, it inhibits pain signal transmission by agonizing the μ-opioid receptor, and on the other hand, it inhibits norepinephrine reuptake to enhance the activity of the pain inhibition pathway. While the two mechanisms act synergistically to exert analgesic effects, they reduce the gastrointestinal adverse reactions and addiction risk of traditional opioids. Clinically, it is mainly used for the treatment of moderate to severe acute pain in adults and pain related to diabetic peripheral neuropathy, especially suitable for chronic pain patients who require long-term analgesia.

At present, the global market size of tapentadol has exceeded 1.2 billion US dollars, with a compound annual growth rate of approximately 7.2% in the past five years. The growth momentum mainly comes from the rising prevalence of chronic pain and the increasing clinical demand for analgesics with low addiction potential. The Chinese market is still in the early stage of development. With the improvement of domestic diagnosis and treatment specifications for analgesics and the inclusion of relevant varieties in medical insurance, the market growth rate is expected to remain above 15% in the next three years. In terms of the competitive landscape, the original research product still occupies the major global market share. At present, only a small number of domestic enterprises have submitted marketing applications for generic drugs, and the supply gap of API is relatively obvious.

The original research enterprise of tapentadol is Grünenthal GmbH of Germany, with the original brand name Palexia. Its core compound patent expired in Europe in 2021, the compound patent in the US market expired in 2022, and the compound patent in China expired in 2023. The main formulations approved by the original research include immediate-release tablets, sustained-release tablets and injections, with common specifications covering 50mg, 100mg, 150mg, 200mg, etc. The original sustained-release tablets and immediate-release tablets are all listed in the FDA Reference Listed Drug Catalog, and the original research products have also been included in the China *Catalog of Reference Preparations for Chemical Drugs*. Up to now, no enterprise in China has obtained the approval number for tapentadol API, only a small number of API registration applications under review can be found on the CDE platform, and all preparations approved for marketing in China are imported original research products. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for tapentadol API, covering impurities in each link of the synthesis route and degradation products. The products meet the compliance requirements of multiple regulations including the Chinese Pharmacopoeia and FDA. Most impurities are in stock, and in-stock products ordered before 16:00 can be shipped on the same day, which can fully meet the reference standard needs of pharmaceutical enterprises in the stages of API R&D, quality research and generic drug declaration.